Literature DB >> 9373202

Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship.

A Raza1, S Alvi, R Z Borok, L Span, A Parcharidou, D Alston, S Rifkin, E Robin, R Shah, S A Gregory.   

Abstract

The paradox of pancytopenia despite cellular bone marrows (BM) was investigated in 120 patients with myelodysplastic syndromes (MDS). Detailed cell cycle kinetics were examined following in vivo infusions of iodo--and/or bromodeoxyuridine (IUdR/BrdU), while the incidence of apoptosis was measured by in situ end labeling (ISEL) of fragmented DNA. Results showed that MDS are highly proliferative disorders with an equally high incidence of apoptotic intramedullary cell death accounting for the paradox of cellularity/cytopenia. By double-labeling BM biopsy sections for ISEL/BrdU we found the peculiar situation of "signal antonymy" where S-phase cells were frequently apoptotic, a phenomenon so far only seen in MDS biopsies. The cause-effect relationship of this excessive proliferation/apoptosis is discussed at length.

Entities:  

Mesh:

Year:  1997        PMID: 9373202     DOI: 10.3109/10428199709068277

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function.

Authors:  Yi Zhang; Sandra Stehling-Sun; Kimberly Lezon-Geyda; Subhash C Juneja; Lucie Coillard; Gouri Chatterjee; Charles A Wuertzer; Fernando Camargo; Archibald S Perkins
Journal:  Blood       Date:  2011-06-10       Impact factor: 22.113

Review 2.  Genetics of progression from MDS to secondary leukemia.

Authors:  Andrew J Menssen; Matthew J Walter
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 3.  The role of apoptosis in the pathogenesis of the myelodysplastic syndromes.

Authors:  Jane E Parker; Ghulam J Mufti
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

4.  Ectopic expression of C/EBPalpha and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasia.

Authors:  Christian R Geest; Miranda Buitenhuis; Edo Vellenga; Paul J Coffer
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

5.  Haploinsufficiency of Apc leads to ineffective hematopoiesis.

Authors:  Jianghong Wang; Anthony A Fernald; John Anastasi; Michelle M Le Beau; Zhijian Qian
Journal:  Blood       Date:  2010-01-11       Impact factor: 22.113

6.  Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome.

Authors:  Wolf C Prall; Akos Czibere; Franck Grall; Dimitrios Spentzos; Ulrich Steidl; Aristoteles Achilles Nikolaus Giagounidis; Andrea Kuendgen; Hasan Otu; Astrid Rong; Towia A Libermann; Ulrich Germing; Norbert Gattermann; Rainer Haas; Manuel Aivado
Journal:  Int J Hematol       Date:  2009-01-20       Impact factor: 2.490

Review 7.  Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.

Authors:  W Li; K Morrone; S Kambhampati; B Will; U Steidl; A Verma
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

8.  A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.

Authors:  Haley E Ramsey; Melissa A Fischer; Taekyu Lee; Agnieszka E Gorska; Maria Pia Arrate; Londa Fuller; Kelli L Boyd; Stephen A Strickland; John Sensintaffar; Leah J Hogdal; Gregory D Ayers; Edward T Olejniczak; Stephen W Fesik; Michael R Savona
Journal:  Cancer Discov       Date:  2018-09-05       Impact factor: 39.397

9.  Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.

Authors:  L Yang; A Mailloux; D E Rollison; J S Painter; J Maciejewski; R L Paquette; T P Loughran; K McGraw; H Makishima; R Radhakrishnan; S Wei; X Ren; R Komrokji; A F List; P K Epling-Burnette
Journal:  Leukemia       Date:  2012-10-17       Impact factor: 11.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.